Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 28, 2023
Serum inducible protein 10 kDa/C-X-C motif chemokine 10 levels predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agentsYoshihito Nagura, Takanori Suzuki, Kentaro Matsuura, et al.Virus Research|December 26, 2025
Optimization of lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes for in vivo delivery of a CRISPR/Cas9 system targeting hepatitis B virusRupaly Akhter, Bouchra Kitab, Mohammmad Enamul Hoque Kayesh, et al.Journal of Psychiatric Research|September 27, 2017
Plasma amino acid profile in major depressive disorder: Analyses in two independent case-control sample setsShintaro Ogawa, Norie Koga, Kotaro Hattori, et al.Journal of Global Health|November 12, 2022
Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West AfricaJeanne Perpétue Vincent, Gibril Ndow, Shintaro Ogawa, et al.Molecular Biology Reports|October 30, 2021
Blocking neddylation elicits antiviral effect against hepatitis B virus replicationKarima Abounouh, Mohammad Enamul Hoque Kayesh, Haya Altawalah, et al.Journal of Gastroenterology|April 28, 2022
Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivationTakanori Suzuki, Takako Inoue, Kentaro Matsuura, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 24, 2022
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assayShinya Hagiwara, Shigeru Kusumoto, Takako Inoue, et al.Virus Research|October 13, 2020
Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNAMohammad Enamul Hoque Kayesh, Yutaka Amako, Md Abul Hashem, et al.Plos One|September 10, 2015
Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New RegimensNobuharu Tamaki, Masayuki Kurosaki, Mayu Higuchi, et al.Alimentary Pharmacology & Therapeutics|October 12, 2018
Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis BYao-Chun Hsu, Tomi Jun, Yen-Tsung Huang, et al.Pageof 6